Update on Guillain-Barre Syndrome
##plugins.themes.bootstrap3.article.sidebar##
PDF (Español (España))
FLIP
HTML (Español (España))
##plugins.themes.bootstrap3.article.main##
Guillain-Barré Syndrome is the most common cause of acute, non-traumatic flaccid paralysis in the world. It is a neurological emergency, causing a rapidly progressive polyneuropathy of sudden onset, generally with lower limb and lumbar pain, muscle weakness and paresthesias, progressing into an ascending symmetric paralysis with areflexia. Life-threatening consequences can occur if the respiratory muscles, cranial nerves or components of the autonomic system are compromised. Clinical presentation encompasses seven different subtypes associated with the immune agents involved in its pathophysiology. Diagnosis is based on clinical presentation, with electrophysiological findings comfirming a demyelinating pattern, F wave, and H reflex abnormalities. Cerebrospinal Fluid characteristic findings include albumino-cytological dissociation: an elevated protein level without an increase in cell count.
Downloads
##plugins.themes.bootstrap3.article.details##
Guillain G BJ, Strohl A. Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellilaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux.Bull Soc Med Hop Paris. 1916;1462–70.
Dimachkie MM, Barohn RJ. Guillain-Barre syndrome and variants. Neurologic clinics. 2013;31(2):491-510.
Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome.
The Lancet Neurology. 2008;7(10):939-50.
Van Den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain-Barre syndrome:pathogenesis, diagnosis, treatment and prognosis. Nature reviews Neurology. 2014;10(8):469-82.
Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R. Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60(7):1146-50.
Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. The Journal of infectious
diseases. 1997;176 Suppl 2:S92-8.
Alter M. The epidemiology of Guillain-Barre syndrome. Annals of neurology. 1990;27 Suppl:S7-12.
Mcgrogan A, MADLE GC, SEAMAN HE, DE VRIES CS. The epidemiology of Guillain-Barre syndrome worldwide.
A systematic literature review. Neuroepidemiology. 2009;32(2):150-63.
B urns TM. Guillain-Barre syndrome. Seminars in neurology. 2008;28(2):152-67.
Jacobs BC, Rothbarth PH, Van Der Meche FG, Herbrink P, Schmitz PI, De Klerk MA, ET AL. The spectrum of
antecedent infections in Guillain-Barre syndrome: a casecontrol study. Neurology. 1998;51(4):1110-5.
Visser LH, Van Der Meche FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, et al. Cytomegalovirus infection
and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group. Neurology. 1996;47(3):668-73.
Santos NQ, Azoubel AC, Lopes AA, Costa G, Bacellar A. Guillain-Barre syndrome in the course of dengue:
case report. Arquivos de neuro-psiquiatria. 2004; 62(1):144-6.
Chen TY, Lee CT. Guillain-Barre syndrome following dengue fever. Annals of emergency medicine. 2007;50(1):94-5.
Esack A, Teelucksingh S, Singh N. The Guillain-Barre syndrome following dengue fever. The West Indian medical journal. 1999;48(1):36-7.
Musso D, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of dengue and chikungunya? Lancet (London, England). 2015;386(9990):243-4.
Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, ET AL. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet (London,England). 2016;387(10027):1531-9.
Smith DW, Mackenzie J. Zika virus and Guillain-Barre syndrome: another viral cause to add to the list. Lancet
(London, England). 2016;387(10027):1486-8.
Solomon T, Baylis M, Brown D. Zika virus and neurological disease-approaches to the unknown. The Lancet Infectious diseases. 2016;16(4):402-4.
Villamil-Gómez W, Silvera LA, Paez-Castellanos J, Rodriguez-Morales AJ. Guillain-Barre syndrome after Chikungunya infection: A case in Colombia. Enfermedades infecciosas y microbiología clínica. 2016;34(2):140-1.
Oehler E, Fournier E, Leparc-Goffart I, Larre P, Cubizolle S, Sookhareea C, ET AL. Increase in cases of Guillain-Barre syndrome during a Chikungunya outbreak, French Polynesia, 2014 to 2015. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2015;20(48):30079.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, ET AL. Guillain-
Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976—1977. American journal of epidemiology. 1979;110(2):105-23.
Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, ET AL. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. The New England journal of medicine. 1998;339(25):1797-802.
Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barre
syndrome in the United Kingdom, 1992 to 2000. Archives of internal medicine. 2006;166(12):1301-4.
Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barre
syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet
(London, England). 2013;381(9876):1461-8.
Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, Li CY, et al. Localization of major gangliosides in the PNS:
implications for immune neuropathies. Brain : a journal of neurology. 2002;125(Pt 11):2491-506.
Kusunoki S, Kaida K, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome: new aspects of research. Biochimica et biophysica acta. 2008;1780(3):441-4.
Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen for serum antibody in Guillain-Barre syndrome. Neurology.1996;47(1):237-42.
Kusunoki S, Mashiko H, Mochizuki N, Chiba A, Arita M, Hitoshi S, ET AL. Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle & nerve. 1997;20(7):840-5.
Jacobs BC, Endtz H, Van Der Meche FG, Hazenberg MP, Achtereekte HA, Van Doorn PA. Serum anti-GQ1b
IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Annals of Neurology.1995;37(2):260-4.
Jacobs BC, Koga M, Van Rijs W, Geleijns K, Van Doorn PA, Willison HJ, et al. Subclass IgG to motor gangliosides
related to infection and clinical course in Guillain-Barre syndrome. Journal of neuroimmunology. 2008;194(1-2):181-90.
Yuki N, Taki T, Handa S. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barre syndrome subsequent to Campylobacter jejuni enteritis. Journal of neuroimmunology. 1996;71(1-2):155-61.
Yuki N, Ho TW, Tagawa Y, Koga M, Li CY, Hirata K, et al. Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. Journal of the neurological sciences. 1999;164(2):134-8.
Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. The Lancet Infectious diseases. 2001;1(1):29-37.
Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology. 1993;43(2):414-7.
Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T. An immunologic abnormality common to Bickerstaff’s brain stem encephalitis and Fisher’s syndrome. Journal of the neurological sciences. 1993;118(1):83-7.
Hughes RA, Hadden RD, Gregson NA, Smith KJ.Pathogenesis of Guillain-Barre syndrome. Journal of neuroimmunology. 1999;100(1-2):74-97.
Fujimura H. The Guillain-Barre syndrome. Handbook of clinical neurology. 2013;115:383-402.
Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine. 1969;48(3):173-215.
Prineas JW. Pathology of the Guillain-Barre syndrome. Annals of neurology. 1981;9 Suppl:6-19.
Willison HJ, Jacobs BC, Van Doorn PA. Guillain-Barre syndrome. Lancet (London, England). 2016;388(10045):717-27.
Arcila-Londono X, Lewis RA. Guillain-Barre syndrome. Seminars in neurology. 2012;32(3):179-86.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Annals of neurology. 1990;27 Suppl:S21-4.
Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain : a journal of neurology. 2014;137(Pt 1):33-43.
Yuki N, Hartung HP. Guillain-Barre syndrome. The New England journal of medicine. 2012;366(24):2294-304.
Walgaard C, Lingsma HF, Ruts L, Drenthen J, Van Konings Veld R, GARSSEN MJ, ET AL. Prediction of respiratory
insufficiency in Guillain-Barre syndrome. Annals of neurology. 2010;67(6):781-7.
Plasmapheresis and Acute Guillain-Barre Syndrome. The Guillain-Barre syndrome Study Group. Neurology. 1985;35(8):1096-104.
Efficiency of Plasma Exchange in Guillain-Barre syndrome: Role of Replacement Fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Annals of neurology. 1987;22(6):753-61.
Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert review of neurotherapeutics. 2009;9(9):1331-9.
Kleyweg RP, Van Der Meche FG, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology. 1988;38(10):1639-41.
Van Der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. The New England journal of medicine. 1992;326(17):1123-9.
Randomised Trial of Plasma Exchange, Intravenous Immunoglobulin, and Combined Treatments In Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre syndrome Trial Group. Lancet (London,England). 1997;349(9047):225-30.
Hughes RA, Van Doorn PA. Corticosteroids for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2012(8):Cd001446.
Van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, Van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet (London, England). 2004; 363(9404):192-6.
Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2013(2):Cd008630.
Netto AB, Taly AB, Kulkarni GB, Rao UG, Rao S. Mortality in mechanically ventilated patients of Guillain Barre syndrome. Annals of Indian Academy of Neurology. 2011;14(4):262-6.
Van Den Berg B, Bunschoten C, Van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013;80(18):1650-4.
Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in south east England. Journal of neurology, neurosurgery, and psychiatry. 1998;64(1):74-7.
Visser LH, Schmitz PI, Meulstee J, Van Doorn PA, Van Der Meche FG. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group. Neurology. 1999;53(3):598-604.
Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. Journal of neurology, neurosurgery, and psychiatry. 2012;83(7):711-8.
González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barre syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC neurology. 2013;13:95.
Fourrier F, Robriquet L, Hurtevent JF, Spagnolo S. A simple functional marker to predict the need for prolonged mechanical ventilation in patients with Guillain-Barre syndrome. Critical care (London, England). 2011;15(1):R65.
Van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, Van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. The Lancet Neurology. 2007;6(7):589-94.
Garssen MP, Van Koningsveld R, Van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome. Journal of neurology. 2006;253(9):1143-6.
